Extended Release Drugs Market
Description
Extended Release Drugs Market
Extended Release Drugs: Market Insights
Drug delivery systems are engineered technologies for controlled release of drugs or to the targeted delivery of drugs. Drug delivery system is a kind of formulation that enables the administration of therapeutic agents in the body and improves its safety and efficacy by controlling the time, rate and place of drug release in the body. Most of the conventional oral products of drugs are formulated to release the active ingredient as soon as it is administered. Now the pattern has been changed to modified release dosage forms to achieve better therapeutic target. Extended release drugs is a type of dosage forms which allows a two-fold reduction in frequency of dosage administered in the body. FDA has enabled certain guidelines for the extended release drugs such as notification in changing the safety labelling of extended release drugs.
Extended Release Drugs: Market Dynamics
Extended release drugs is likely to trigger growth in the market owing to increasing acceptance of different dosage forms, growing pediatric and geriatric population is likely to witness significant growth in the market. Moreover increasing research and development and ongoing clinical trials seems to spur the growth of the extended release drugs market. Also increasing focus in innovation and development of novel therapeutics adds another factor in increasing the growth of the extended release drugs market. However, there are certain limitation that may hamper the growth of the market such as cost of the extended release drugs. For example, Namenda extended release drugs cost around US$ 494 for 7mg. Apart from this, extended release drugs have a have a slower onset of action and may cause potential side effects. All this factors is likely to hamper the growth of the extended release drugs market.
Extended Release Drugs Market: Segmentation
The global extended release drugs market is segmented by drug release types and distributional channel
Extended Release Drugs Market Segmentation by Drug Release
Sustained Release
Controlled Release
Extended Release Drugs Market Segmentation by Distributional Channel
Hospital Pharmacies
Retail Pharmacies
Mail Order Pharmacies
Drug Stores
Extended Release Drugs Market: Overview
Extended release drugs is expected to anticipate significant growth in the market. Manufacturers are currently focus in developing drugs that actively acts on the target. Various extended release drugs has been approved by FDA for the treatment chronic diseases such as Opana ER by Endo Pharmaceuticals, Nucynta ER by Janssen Pharmaceuticals, Exalgo by Mallinckrodt, Fentanyl by Actavis, Avinza by Pfizer etc. Extended release drugs mostly include special coating that make the drug to stay for a longer period of time. Extended release drugs is mostly used to prevent from chronic pain and other diseases. Thus, with increasing prevalence, the extended release drugs will boost the growth of the market.
Extended Release Drugs: Region-wise Outlook
On the basis of geography, the global extended release drugs market is segmented into seven key regions: North America, Latin America, Western Europe, Eastern Europe, and Asia Pacific excluding Japan and Middle East & Africa. North America holds significant revenue share in the extended release drugs market due to rising adoption of novel therapeutics and growing investments in research and development will propel the growth of extended release drugs market. Europe market witness to trigger the growth of the extended release drugs market due to significant rise in prevalence of chronic diseases such as cancer, COPD, diabetes etc. and increasing approval of novel drugs will boost the growth of the extended release drugs market. Asia Pacific also have the potential in fostering the growth of the extended release drugs market due to increasing pharmaceutical companies in development of various diseases. Japan seems to have significant potential to grow in the overall extended release drugs market due to growing number of geriatric population. Middle East & Africa have relatively less growth in extended release drugs market due to lack of investment in research and development and low economy growth which as a result will hinder the growth of the extended release drugs market.
Extended Release Drugs Market: Key Players
Some of the key players present across the value chain of the global extended release drugs market are Pfizer, Mallinckrodt, Actavis, Janssen Pharmaceuticals, Endo Pharmaceuticals, Purdue Pharma, Lavipharm Labs, Mylan Technologies, Noven, Aveva, Watson, Impax, Ranbaxy and others
The report covers exhaustive analysis on:
Market Segments
Market Dynamics
Market Size
Current Trends/Issues/Challenges
Competition & Companies involved
Value Chain
The regional analysis includes:
North America (U.S., Canada)
Latin America (Mexico. Brazil)
Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
Eastern Europe (Poland, Russia)
Asia-Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
Japan
The Middle East and Africa (GCC, S. Africa, N. Africa)
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Report Highlights:
Detailed overview of parent market
Changing market dynamics in the industry
In-depth market segmentation
Historical, current and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.
Table of Contents
250 Pages
- 1. Executive Summary | Extended Release Drugs Market
- 1.1. Global Market Outlook
- 1.2. Demand-side Trends
- 1.3. Supply-side Trends
- 1.4. Technology Roadmap Analysis
- 1.5. Analysis and Recommendations
- 2. Market Overview
- 2.1. Market Coverage / Taxonomy
- 2.2. Market Definition / Scope / Limitations
- 3. Market Background
- 3.1. Market Dynamics
- 3.1.1. Drivers
- 3.1.2. Restraints
- 3.1.3. Opportunity
- 3.1.4. Trends
- 3.2. Scenario Forecast
- 3.2.1. Demand in Optimistic Scenario
- 3.2.2. Demand in Likely Scenario
- 3.2.3. Demand in Conservative Scenario
- 3.3. Opportunity Map Analysis
- 3.4. Product Life Cycle Analysis
- 3.5. Supply Chain Analysis
- 3.5.1. Supply Side Participants and Their Roles
- 3.5.1.1. Producers
- 3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)
- 3.5.1.3. Wholesalers and Distributors
- 3.5.2. Value Added and Value Created at Node in the Supply Chain
- 3.5.3. List of Raw Material Suppliers
- 3.5.4. List of Existing and Potential Buyers
- 3.6. Investment Feasibility Matrix
- 3.7. Value Chain Analysis
- 3.7.1. Profit Margin Analysis
- 3.7.2. Wholesalers and Distributors
- 3.7.3. Retailers
- 3.8. PESTLE and Porter’s Analysis
- 3.9. Regulatory Landscape
- 3.9.1. By Key Regions
- 3.9.2. By Key Countries
- 3.10. Regional Parent Market Outlook
- 3.11. Production and Consumption Statistics
- 3.12. Import and Export Statistics
- 4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032
- 4.1. Historical Market Size Value (US$ Million) & Volume (Tons) Analysis, 2017 to 2021
- 4.2. Current and Future Market Size Value (US$ Million) & Volume (Tons) Projections, 2022 to 2032
- 4.2.1. Y-o-Y Growth Trend Analysis
- 4.2.2. Absolute $ Opportunity Analysis
- 5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Drug Release
- 5.1. Introduction / Key Findings
- 5.2. Historical Market Size Value (US$ Million) & Volume (Tons) Analysis By Drug Release, 2017 to 2021
- 5.3. Current and Future Market Size Value (US$ Million) & Volume (Tons) Analysis and Forecast By Drug Release, 2022 to 2032
- 5.3.1. Sustained Release
- 5.3.2. Controlled Release
- 5.4. Y-o-Y Growth Trend Analysis By Drug Release, 2017 to 2021
- 5.5. Absolute $ Opportunity Analysis By Drug Release, 2022 to 2032
- 6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Distributional Channel
- 6.1. Introduction / Key Findings
- 6.2. Historical Market Size Value (US$ Million) & Volume (Tons) Analysis By Distributional Channel, 2017 to 2021
- 6.3. Current and Future Market Size Value (US$ Million) & Volume (Tons) Analysis and Forecast By Distributional Channel, 2022 to 2032
- 6.3.1. Hospital Pharmacies
- 6.3.2. Retail Pharmacies
- 6.3.3. Mail Order Pharmacies
- 6.3.4. Drug Stores
- 6.4. Y-o-Y Growth Trend Analysis By Distributional Channel, 2017 to 2021
- 6.5. Absolute $ Opportunity Analysis By Distributional Channel, 2022 to 2032
- 7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
- 7.1. Introduction
- 7.2. Historical Market Size Value (US$ Million) & Volume (Tons) Analysis By Region, 2017 to 2021
- 7.3. Current Market Size Value (US$ Million) & Volume (Tons) Analysis and Forecast By Region, 2022 to 2032
- 7.3.1. North America
- 7.3.2. Latin America
- 7.3.3. Europe
- 7.3.4. East Asia
- 7.3.5. South Asia & Pacific
- 7.3.6. Middle East and Africa
- 7.4. Market Attractiveness Analysis By Region
- 8. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
- 8.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017 to 2021
- 8.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2022 to 2032
- 8.2.1. By Country
- 8.2.1.1. USA
- 8.2.1.2. Canada
- 8.2.2. By Drug Release
- 8.2.3. By Distributional Channel
- 8.3. Market Attractiveness Analysis
- 8.3.1. By Country
- 8.3.2. By Drug Release
- 8.3.3. By Distributional Channel
- 8.4. Key Takeaways
- 9. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
- 9.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017 to 2021
- 9.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2022 to 2032
- 9.2.1. By Country
- 9.2.1.1. Brazil
- 9.2.1.2. Mexico
- 9.2.1.3. Rest of Latin America
- 9.2.2. By Drug Release
- 9.2.3. By Distributional Channel
- 9.3. Market Attractiveness Analysis
- 9.3.1. By Country
- 9.3.2. By Drug Release
- 9.3.3. By Distributional Channel
- 9.4. Key Takeaways
- 10. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
- 10.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017 to 2021
- 10.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2022 to 2032
- 10.2.1. By Country
- 10.2.1.1. Germany
- 10.2.1.2. United Kingdom
- 10.2.1.3. France
- 10.2.1.4. Spain
- 10.2.1.5. Italy
- 10.2.1.6. Rest of Europe
- 10.2.2. By Drug Release
- 10.2.3. By Distributional Channel
- 10.3. Market Attractiveness Analysis
- 10.3.1. By Country
- 10.3.2. By Drug Release
- 10.3.3. By Distributional Channel
- 10.4. Key Takeaways
- 11. East Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
- 11.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017 to 2021
- 11.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2022 to 2032
- 11.2.1. By Country
- 11.2.1.1. China
- 11.2.1.2. Japan
- 11.2.1.3. South Korea
- 11.2.2. By Drug Release
- 11.2.3. By Distributional Channel
- 11.3. Market Attractiveness Analysis
- 11.3.1. By Country
- 11.3.2. By Drug Release
- 11.3.3. By Distributional Channel
- 11.4. Key Takeaways
- 12. South Asia & Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
- 12.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017 to 2021
- 12.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2022 to 2032
- 12.2.1. By Country
- 12.2.1.1. India
- 12.2.1.2. Thailand
- 12.2.1.3. Indonesia
- 12.2.1.4. Malaysia
- 12.2.1.5. Singapore
- 12.2.1.6. Australia
- 12.2.1.7. New Zealand
- 12.2.1.8. Rest of South Asia & Pacific
- 12.2.2. By Drug Release
- 12.2.3. By Distributional Channel
- 12.3. Market Attractiveness Analysis
- 12.3.1. By Country
- 12.3.2. By Drug Release
- 12.3.3. By Distributional Channel
- 12.4. Key Takeaways
- 13. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
- 13.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017 to 2021
- 13.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2022 to 2032
- 13.2.1. By Country
- 13.2.1.1. GCC Countries
- 13.2.1.2. South Africa
- 13.2.1.3. Israel
- 13.2.1.4. Rest of Middle East and Africa
- 13.2.2. By Drug Release
- 13.2.3. By Distributional Channel
- 13.3. Market Attractiveness Analysis
- 13.3.1. By Country
- 13.3.2. By Drug Release
- 13.3.3. By Distributional Channel
- 13.4. Key Takeaways
- 14. Key Countries Market Analysis
- 14.1. USA
- 14.1.1. Pricing Analysis
- 14.1.2. Market Share Analysis, 2021
- 14.1.2.1. By Drug Release
- 14.1.2.2. By Distributional Channel
- 14.2. Canada
- 14.2.1. Pricing Analysis
- 14.2.2. Market Share Analysis, 2021
- 14.2.2.1. By Drug Release
- 14.2.2.2. By Distributional Channel
- 14.3. Brazil
- 14.3.1. Pricing Analysis
- 14.3.2. Market Share Analysis, 2021
- 14.3.2.1. By Drug Release
- 14.3.2.2. By Distributional Channel
- 14.4. Mexico
- 14.4.1. Pricing Analysis
- 14.4.2. Market Share Analysis, 2021
- 14.4.2.1. By Drug Release
- 14.4.2.2. By Distributional Channel
- 14.5. Germany
- 14.5.1. Pricing Analysis
- 14.5.2. Market Share Analysis, 2021
- 14.5.2.1. By Drug Release
- 14.5.2.2. By Distributional Channel
- 14.6. United Kingdom
- 14.6.1. Pricing Analysis
- 14.6.2. Market Share Analysis, 2021
- 14.6.2.1. By Drug Release
- 14.6.2.2. By Distributional Channel
- 14.7. France
- 14.7.1. Pricing Analysis
- 14.7.2. Market Share Analysis, 2021
- 14.7.2.1. By Drug Release
- 14.7.2.2. By Distributional Channel
- 14.8. Spain
- 14.8.1. Pricing Analysis
- 14.8.2. Market Share Analysis, 2021
- 14.8.2.1. By Drug Release
- 14.8.2.2. By Distributional Channel
- 14.9. Italy
- 14.9.1. Pricing Analysis
- 14.9.2. Market Share Analysis, 2021
- 14.9.2.1. By Drug Release
- 14.9.2.2. By Distributional Channel
- 14.10. China
- 14.10.1. Pricing Analysis
- 14.10.2. Market Share Analysis, 2021
- 14.10.2.1. By Drug Release
- 14.10.2.2. By Distributional Channel
- 14.11. Japan
- 14.11.1. Pricing Analysis
- 14.11.2. Market Share Analysis, 2021
- 14.11.2.1. By Drug Release
- 14.11.2.2. By Distributional Channel
- 14.12. South Korea
- 14.12.1. Pricing Analysis
- 14.12.2. Market Share Analysis, 2021
- 14.12.2.1. By Drug Release
- 14.12.2.2. By Distributional Channel
- 14.13. India
- 14.13.1. Pricing Analysis
- 14.13.2. Market Share Analysis, 2021
- 14.13.2.1. By Drug Release
- 14.13.2.2. By Distributional Channel
- 14.14. Thailand
- 14.14.1. Pricing Analysis
- 14.14.2. Market Share Analysis, 2021
- 14.14.2.1. By Drug Release
- 14.14.2.2. By Distributional Channel
- 14.15. Indonesia
- 14.15.1. Pricing Analysis
- 14.15.2. Market Share Analysis, 2021
- 14.15.2.1. By Drug Release
- 14.15.2.2. By Distributional Channel
- 14.16. Malaysia
- 14.16.1. Pricing Analysis
- 14.16.2. Market Share Analysis, 2021
- 14.16.2.1. By Drug Release
- 14.16.2.2. By Distributional Channel
- 14.17. Singapore
- 14.17.1. Pricing Analysis
- 14.17.2. Market Share Analysis, 2021
- 14.17.2.1. By Drug Release
- 14.17.2.2. By Distributional Channel
- 14.18. Australia
- 14.18.1. Pricing Analysis
- 14.18.2. Market Share Analysis, 2021
- 14.18.2.1. By Drug Release
- 14.18.2.2. By Distributional Channel
- 14.19. New Zealand
- 14.19.1. Pricing Analysis
- 14.19.2. Market Share Analysis, 2021
- 14.19.2.1. By Drug Release
- 14.19.2.2. By Distributional Channel
- 14.20. GCC Countries
- 14.20.1. Pricing Analysis
- 14.20.2. Market Share Analysis, 2021
- 14.20.2.1. By Drug Release
- 14.20.2.2. By Distributional Channel
- 14.21. South Africa
- 14.21.1. Pricing Analysis
- 14.21.2. Market Share Analysis, 2021
- 14.21.2.1. By Drug Release
- 14.21.2.2. By Distributional Channel
- 14.22. Israel
- 14.22.1. Pricing Analysis
- 14.22.2. Market Share Analysis, 2021
- 14.22.2.1. By Drug Release
- 14.22.2.2. By Distributional Channel
- 15. Market Structure Analysis
- 15.1. Competition Dashboard
- 15.2. Competition Benchmarking
- 15.3. Market Share Analysis of Top Players
- 15.3.1. By Regional
- 15.3.2. By Drug Release
- 15.3.3. By Distributional Channel
- 16. Competition Analysis
- 16.1. Competition Deep Dive
- 16.1.1. Pfizer
- 16.1.1.1. Overview
- 16.1.1.2. Product Portfolio
- 16.1.1.3. Profitability by Market Segments
- 16.1.1.4. Sales Footprint
- 16.1.1.5. Strategy Overview
- 16.1.1.5.1. Marketing Strategy
- 16.1.1.5.2. Product Strategy
- 16.1.1.5.3. Channel Strategy
- 16.1.2. Mallinckrodt
- 16.1.2.1. Overview
- 16.1.2.2. Product Portfolio
- 16.1.2.3. Profitability by Market Segments
- 16.1.2.4. Sales Footprint
- 16.1.2.5. Strategy Overview
- 16.1.2.5.1. Marketing Strategy
- 16.1.2.5.2. Product Strategy
- 16.1.2.5.3. Channel Strategy
- 16.1.3. Actavis
- 16.1.3.1. Overview
- 16.1.3.2. Product Portfolio
- 16.1.3.3. Profitability by Market Segments
- 16.1.3.4. Sales Footprint
- 16.1.3.5. Strategy Overview
- 16.1.3.5.1. Marketing Strategy
- 16.1.3.5.2. Product Strategy
- 16.1.3.5.3. Channel Strategy
- 16.1.4. Janssen Pharmaceuticals
- 16.1.4.1. Overview
- 16.1.4.2. Product Portfolio
- 16.1.4.3. Profitability by Market Segments
- 16.1.4.4. Sales Footprint
- 16.1.4.5. Strategy Overview
- 16.1.4.5.1. Marketing Strategy
- 16.1.4.5.2. Product Strategy
- 16.1.4.5.3. Channel Strategy
- 16.1.5. Endo Pharmaceuticals
- 16.1.5.1. Overview
- 16.1.5.2. Product Portfolio
- 16.1.5.3. Profitability by Market Segments
- 16.1.5.4. Sales Footprint
- 16.1.5.5. Strategy Overview
- 16.1.5.5.1. Marketing Strategy
- 16.1.5.5.2. Product Strategy
- 16.1.5.5.3. Channel Strategy
- 16.1.6. Purdue Pharma
- 16.1.6.1. Overview
- 16.1.6.2. Product Portfolio
- 16.1.6.3. Profitability by Market Segments
- 16.1.6.4. Sales Footprint
- 16.1.6.5. Strategy Overview
- 16.1.6.5.1. Marketing Strategy
- 16.1.6.5.2. Product Strategy
- 16.1.6.5.3. Channel Strategy
- 16.1.7. Lavipharm Labs
- 16.1.7.1. Overview
- 16.1.7.2. Product Portfolio
- 16.1.7.3. Profitability by Market Segments
- 16.1.7.4. Sales Footprint
- 16.1.7.5. Strategy Overview
- 16.1.7.5.1. Marketing Strategy
- 16.1.7.5.2. Product Strategy
- 16.1.7.5.3. Channel Strategy
- 16.1.8. Viatris
- 16.1.8.1. Overview
- 16.1.8.2. Product Portfolio
- 16.1.8.3. Profitability by Market Segments
- 16.1.8.4. Sales Footprint
- 16.1.8.5. Strategy Overview
- 16.1.8.5.1. Marketing Strategy
- 16.1.8.5.2. Product Strategy
- 16.1.8.5.3. Channel Strategy
- 16.1.9. Noven
- 16.1.9.1. Overview
- 16.1.9.2. Product Portfolio
- 16.1.9.3. Profitability by Market Segments
- 16.1.9.4. Sales Footprint
- 16.1.9.5. Strategy Overview
- 16.1.9.5.1. Marketing Strategy
- 16.1.9.5.2. Product Strategy
- 16.1.9.5.3. Channel Strategy
- 16.1.10. Aveva
- 16.1.10.1. Overview
- 16.1.10.2. Product Portfolio
- 16.1.10.3. Profitability by Market Segments
- 16.1.10.4. Sales Footprint
- 16.1.10.5. Strategy Overview
- 16.1.10.5.1. Marketing Strategy
- 16.1.10.5.2. Product Strategy
- 16.1.10.5.3. Channel Strategy
- 16.1.11. Watson
- 16.1.11.1. Overview
- 16.1.11.2. Product Portfolio
- 16.1.11.3. Profitability by Market Segments
- 16.1.11.4. Sales Footprint
- 16.1.11.5. Strategy Overview
- 16.1.11.5.1. Marketing Strategy
- 16.1.11.5.2. Product Strategy
- 16.1.11.5.3. Channel Strategy
- 16.1.12. Impax
- 16.1.12.1. Overview
- 16.1.12.2. Product Portfolio
- 16.1.12.3. Profitability by Market Segments
- 16.1.12.4. Sales Footprint
- 16.1.12.5. Strategy Overview
- 16.1.12.5.1. Marketing Strategy
- 16.1.12.5.2. Product Strategy
- 16.1.12.5.3. Channel Strategy
- 16.1.13. Ranbaxy
- 16.1.13.1. Overview
- 16.1.13.2. Product Portfolio
- 16.1.13.3. Profitability by Market Segments
- 16.1.13.4. Sales Footprint
- 16.1.13.5. Strategy Overview
- 16.1.13.5.1. Marketing Strategy
- 16.1.13.5.2. Product Strategy
- 16.1.13.5.3. Channel Strategy
- 17. Assumptions & Acronyms Used
- 18. Research Methodology
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
